Dendreon stock price

Dendreon's Infectious Influence on Biotechs

One of Thursday's hardest-hit stocks was Dendreon, maker of the prostate cancer vaccine Provenge, which plunged 67% after reporting disappointing results. But, weirdly, Debdreon's disease seemed to infect the entire sector, dragging down companies with proven drugs. Are biotechs bargains right now?

Dendreon Shares Slide on Medicare Payment Worries

The stock sank on Thursday after the Centers for Medicare and Medicaid Services said it was evaluating data on Provenge, the company's prostate cancer vaccine, to decide whether to cover the drug for seniors nationwide.